{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:07:22Z","timestamp":1793142442933,"version":"4.5.0"},"reference-count":61,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The primary objective of this randomized, double-blind, placebo-controlled, multicenter phase II study (Alliance A221805) was to screen two doses of duloxetine for preventing sensory oxaliplatin-induced peripheral neuropathy (OIPN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Participants were randomly assigned 1:1:1 to receive once daily 30 mg duloxetine, 60 mg duloxetine, or placebo. Eligible participants had stage II to III colorectal cancer and no baseline neuropathy, had Eastern Cooperative Oncology Group performance status 0-2, were age 25 years and older, and received oxaliplatin via one of the following doses and schedules: 85 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 2 weeks (6 or 12 doses) or 130 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 3 weeks (4 doses). Duloxetine\/placebo was taken once daily beginning day 1 of cycle 1 and continued for 17 weeks. The primary end point, a composite response reflecting sensory OIPN symptom severity and onset, was measured in weeks 19-21 using a validated participant-reported outcome survey assessing extremity numbness, tingling, and pain. Response was defined as a participant-reported highest score of \u22642 (ie, 1 = not at all; 2 = a little) on survey items. To be evaluable for the response end point, eligible participants must have initiated oxaliplatin and submitted \u22651 postbaseline OIPN survey.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 199 participants (n = 66, 30 mg duloxetine; n = 66, 60 mg duloxetine; n = 67, placebo), 46, 47, and 50 (N = 143, 71.8%), respectively, were evaluable for primary end point analysis based on modified intention-to-treat criteria. Participant mean age was 55.1 years (standard deviation = 10.4). Most were White (n = 113, 80.7%) and male (n = 82, 58.6%). The proportion of responders among those receiving placebo (68.0%) was similar to those receiving duloxetine 30 mg (65.2%) or 60 mg (66.0%). Duloxetine adherence rates, measured via pill counts\u201430 mg (54%), 60 mg (57%), and placebo (59%) groups\u2014were low (&lt;75%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Duloxetine is not more promising than placebo for preventing sensory OIPN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/oa-25-00107","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:59:08Z","timestamp":1774468748000},"source":"Crossref","is-referenced-by-count":4,"title":["Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study"],"prefix":"10.1200","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct04137107","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-6636","authenticated-orcid":true,"given":"Ellen M.","family":"Lavoie Smith","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-4319","authenticated-orcid":true,"given":"Minji","family":"Lee","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5330-8811","authenticated-orcid":true,"given":"Mary R.","family":"Scott","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Hillman","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5186-0122","authenticated-orcid":true,"given":"Tracy","family":"Rieken","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wills","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Diaz-Cobo","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chow","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1117-0983","authenticated-orcid":true,"given":"Heidi D.","family":"Finnes","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-332X","authenticated-orcid":true,"given":"Kathryn","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-0898","authenticated-orcid":true,"given":"Jeffrey","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":true,"given":"Eileen","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4690-669X","authenticated-orcid":true,"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[{"name":"Trinity Health Saint Joseph Mercy Hospital, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-1773","authenticated-orcid":true,"given":"Narjust","family":"Florez","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Harvard Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Kharofa","sequence":"additional","affiliation":[{"name":"University of Cincinnati Cancer Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-1059","authenticated-orcid":true,"given":"Rang","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamedtaki","family":"Tejani","sequence":"additional","affiliation":[{"name":"AdventHealth Orlando, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki","family":"Chung","sequence":"additional","affiliation":[{"name":"NCORP of the Carolinas (Prisma Health NCORP), Greenville, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-5146","authenticated-orcid":true,"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5752","authenticated-orcid":true,"given":"Charles","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-5645","authenticated-orcid":true,"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.4539"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21601"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.980912"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.002"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.03.017"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12097"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1556804"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1127-7"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1905-5"},{"key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-020-00903-0","article-title":"The physical consequences of chemotherapy-induced peripheral neuropathy","volume":"22","author":"Tofthagen CS","year":"2020","unstructured":"Tofthagen CS, Cheville AL, Loprinzi CL: The physical consequences of chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 22:50, 2020","journal-title":"Curr Oncol Rep"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3552"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxics11020104"},{"key":"e_1_3_9_16_2","first-page":"913848","article-title":"Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer","volume":"2012","author":"Pike CT","year":"2012","unstructured":"Pike CT, Birnbaum HG, Muehlenbein CE, et al: Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848, 2012","journal-title":"Chemother Res Pract"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3329-5"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"e_1_3_9_19_2","first-page":"395","article-title":"The evaluation of quality of life associated with peripheral neuropathy in patients with hematologic cancer","volume":"12","author":"Usta-Yesilbalkan O","year":"2019","unstructured":"Usta-Yesilbalkan O, Ozkaraman A, Lafci C: The evaluation of quality of life associated with peripheral neuropathy in patients with hematologic cancer. Int J Caring Sci 12:395-402, 2019","journal-title":"Int J Caring Sci"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NNR.0000289503.22414.79"},{"key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/ALN.0b013e3181e89a93","article-title":"Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner","volume":"113","author":"Wang SY","year":"2010","unstructured":"Wang SY, Calderon J, Kuo Wang G: Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113:655-665, 2010","journal-title":"Anesthesiology"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1237-2"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12421"},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/sim.4780050508","article-title":"Calibrated phase II clinical trials in oncology","volume":"5","author":"Herson J","year":"1986","unstructured":"Herson J, Carter SK: Calibrated phase II clinical trials in oncology. Stat Med 5:441-447, 1986","journal-title":"Stat Med"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/aas.12697","article-title":"Prevalence and determinants of medication non-adherence in chronic pain patients: A systematic review","volume":"60","author":"Timmerman L","year":"2016","unstructured":"Timmerman L, Stronks DL, Groeneweg JG, et al: Prevalence and determinants of medication non-adherence in chronic pain patients: A systematic review. Acta Anaesthesiol Scand 60:416-431, 2016","journal-title":"Acta Anaesthesiol Scand"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds329"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0379-8"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke JF","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D'Souza DN, et al: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411-1420, 2006","journal-title":"Neurology"},{"key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein DJ","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, et al: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109-118, 2005","journal-title":"Pain"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211052646"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-022-00824-0"},{"key":"e_1_3_9_36_2","first-page":"493","article-title":"Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)","volume":"32","author":"Aghili M","year":"2024","unstructured":"Aghili M, Taherioun M, Jafari F, et al: Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial). Support Care Cancer 32:493, 2024","journal-title":"Support Care Cancer"},{"key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/10998004231209444","article-title":"Effectiveness of duloxetine on oxaliplatin-induced allodynia and hyperalgesia in rats","volume":"26","author":"Wagner MA","year":"2023","unstructured":"Wagner MA, Smith EML, Ayyash N, et al: Effectiveness of duloxetine on oxaliplatin-induced allodynia and hyperalgesia in rats. Biol Res Nurs 26:248-256, 2023","journal-title":"Biol Res Nurs"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4553-y"},{"key":"e_1_3_9_39_2","first-page":"107327481875660","article-title":"In search of a gold standard patient-reported outcome measure for use in Chemotherapy- induced peripheral neuropathy clinical trials","volume":"25","author":"Smith EML","year":"2018","unstructured":"Smith EML, Knoerl R, Yang JJ, et al: In search of a gold standard patient-reported outcome measure for use in Chemotherapy- induced peripheral neuropathy clinical trials. Cancer Control 25:1073274818756608, 2018","journal-title":"Cancer Control"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1188\/17.ONF.580-588"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0536"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0355"},{"key":"e_1_3_9_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709"},{"key":"e_1_3_9_45_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/EDBK_237443","article-title":"Translating IDEA to practice and beyond: Managing stage II and III Colon cancer","volume":"39","author":"Gill S","year":"2019","unstructured":"Gill S, Meyerhardt JA, Arun M, et al: Translating IDEA to practice and beyond: Managing stage II and III Colon cancer. Am Soc Clin Oncol Educ Book 39:226-235, 2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.06.020"},{"key":"e_1_3_9_47_2","volume-title":"Health NIo: NCI-CTCAE Version 5.0","author":"Institute NC","year":"2017","unstructured":"Institute NC. Health NIo: NCI-CTCAE Version 5.0. Washington, DC: U.S.Department of Health and Human Services, 2017"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/1740774516655101"},{"key":"e_1_3_9_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244"},{"key":"e_1_3_9_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_9_51_2","first-page":"CD003974","article-title":"Placebo interventions for all clinical conditions","volume":"2010","author":"Hrobjartsson A","year":"2010","unstructured":"Hrobjartsson A, Gotzsche PC: Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010:CD003974, 2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_9_52_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","article-title":"Placebo response and effect in randomized clinical trials: Meta-research with focus on contextual effects","volume":"22","author":"Hafliethadottir SH","year":"2021","unstructured":"Hafliethadottir SH, Juhl CB, Nielsen SM, et al: Placebo response and effect in randomized clinical trials: Meta-research with focus on contextual effects. Trials 22:493, 2021","journal-title":"Trials"},{"key":"e_1_3_9_53_2","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","article-title":"Increasing placebo responses over time in U.S. clinical trials of neuropathic pain","volume":"156","author":"Tuttle AH","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, et al: Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156:2616-2626, 2015","journal-title":"Pain"},{"key":"e_1_3_9_54_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/11584300-000000000-00000","article-title":"The placebo response: Relationship to outcomes in trials of postherpetic neuralgia","volume":"30","author":"Irving G","year":"2010","unstructured":"Irving G: The placebo response: Relationship to outcomes in trials of postherpetic neuralgia. Clin Drug Investig 30:739-748, 2010","journal-title":"Clin Drug Investig"},{"key":"e_1_3_9_55_2","doi-asserted-by":"crossref","first-page":"147470491560055","DOI":"10.1177\/1474704915600559","article-title":"The signaling theory of symptoms: An evolutionary explanation of the placebo effect","volume":"13","author":"Steinkopf L","year":"2015","unstructured":"Steinkopf L: The signaling theory of symptoms: An evolutionary explanation of the placebo effect. Evol Psychol 13:1474704915600559, 2015","journal-title":"Evol Psychol"},{"key":"e_1_3_9_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"e_1_3_9_57_2","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1038\/s41598-020-64511-5","article-title":"Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy","volume":"10","author":"Kim SH","year":"2020","unstructured":"Kim SH, Choi MK, Park NY, et al: Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10:7995, 2020","journal-title":"Sci Rep"},{"key":"e_1_3_9_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02755-w"},{"key":"e_1_3_9_59_2","doi-asserted-by":"crossref","first-page":"15593","DOI":"10.1038\/s41598-022-18716-5","article-title":"Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin","volume":"12","author":"Burgess BL","year":"2022","unstructured":"Burgess BL, Cho E, Honigberg L: Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 12:15593, 2022","journal-title":"Sci Rep"},{"key":"e_1_3_9_60_2","doi-asserted-by":"crossref","first-page":"e154395","DOI":"10.1172\/jci.insight.154395","article-title":"Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy","volume":"7","author":"Huehnchen P","year":"2022","unstructured":"Huehnchen P, Schinke C, Bangemann N, et al: Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7:e154395, 2022","journal-title":"JCI Insight"},{"key":"e_1_3_9_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12493"},{"key":"e_1_3_9_62_2","doi-asserted-by":"crossref","first-page":"942960","DOI":"10.3389\/fonc.2022.942960","article-title":"Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers","volume":"12","author":"Kim SH","year":"2022","unstructured":"Kim SH, Kim KH, Hyun JW, et al: Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. Front Oncol 12:942960, 2022","journal-title":"Front Oncol"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:21:28Z","timestamp":1775143288000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/OA-25-00107"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00107","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e2500107"}}